Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1729-1738

  Saadatmand, Sepideh ^a   Obdeijn, Inge Marie ^a   Rutgers, Emiel J ^b   Oosterwijk, Jan C ^c   Tollenaar, Rob A ^d   Woldringh, Gwendolyn H ^e   Bergers, Elisabeth ^f   Verhoef, Cornelis ^a   Heijnsdijk, Eveline A ^a   Hooning, Maartje J ^a   De Koning, Harry J ^a   Tilanus Linthorst, Madeleine M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRCA1; BRCA2; breast cancer survival; familial cancer syndromes; screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; LOCAL METASTASIS; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; METASTASIS FREE SURVIVAL; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR VOLUME; BREAST TUMOR; CASE CONTROL STUDY; CLINICAL TRIAL; EPIDEMIOLOGY; GENETICS; MORTALITY; MULTICENTER STUDY; MUTATION; NETHERLANDS; PROCEDURES; PROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MUTATION; NETHERLANDS; PROSPECTIVE STUDIES;

EID: 84943396487     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29534     Document Type: Article

References (34)

1. National Borstkanker Overleg Nederland (NABON). Richtlijn mammacarcinoom 2012 (Breast Cancer National Guideline 2012). http://oncoline.nl/richtlijn/doc/index.php?type=pda&richtlijn-id=828. Last accessed 7 April 2015.
2. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines): genetic/familial high-risk assessment: breast and ovarian, http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf. Last accessed 7 April 2015.
3. National Institute for Health and Clinical Excellence guidelines (NICE). NICE clinical Guideline 164. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. http://www.nice.org.uk/guidance/cg164/resources/guidance-familial-breast-cancer-pdf. Last accessed 7 April 2015.
4. Kriege M, Brekelmans CT, Boetes C, et al., Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-37.
5. Kuhl CK, Schmutzler RK, Leutner CC, et al., Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215: 267-79.
6. Leach MO, Boggis CR, Dixon AK, et al., Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-78.
7. Kuhl CK, Schrading S, Leutner CC, et al., Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23: 8469-76.
8. Warner E, Plewes DB, Hill KA, et al., Surveillance of brca1 and brca2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317-25.
9. Sardanelli F, Podo F, Santoro F, et al., Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk Italian 1 study): final results. Invest Radiol 2011; 46: 94-105.
10. Saslow D, Boetes C, Burke W, et al., American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57: 75-89.
11. Rijnsburger AJ, Obdeijn IM, Kaas R, et al., BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC screening study. J Clin Oncol Off J Am Soc Clin Oncol 2010; 28: 5265-73.
12. Claus EB, Risch N, Thompson WD,. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73: 643-51.
13. Jacobi CE, de Bock GH, Siegerink B, et al., Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat 2009; 115: 381-90.
14. Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, et al., Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst 2013; 105: 1314-21.
15. Rubin DB,. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 2007; 26: 20-36.
16. National Borstkanker Overleg Nederland (NABON). Richtlijn behandeling van het mammacarcinoom 2005. http://www.oncoline.nl/uploaded/FILES/mammacarcinoom/Richtlijn%20Behandeling%20van%20het%20Mammacarcinoom%20oktober%202005.pdf. Last accessed 7 April 2015.
17. Schemper M, Smith TL,. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-6.
18. Cox B, Sneyd MJ., Bias in breast cancer research in the screening era. Breast 2013 Dec;22(6):1041-5. doi: 10.1016/j.breast.2013.07.046. Epub 2013 Aug 26.
19. Berry DA, Cronin KA, Plevritis SK, et al., Cancer I, surveillance modeling network C. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-92.
20. Heijnsdijk EA, Warner E, Gilbert FJ, et al., Differences in natural history between breast cancers in brca1 and brca2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 2012; 21: 1458-68.
21. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, et al., Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 2011; 33: 111-21.
22. Metcalfe KA, Lubinski J, Ghadirian P, et al., Predictors of contralateral prophylactic mastectomy in women with a brca1 or brca2 mutation: the hereditary breast cancer clinical study group. J Clin Oncol 2008; 26: 1093-7.
23. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al., Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-brca1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007; 43: 867-76.
24. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
25. Kriege M, Seynaeve C, Meijers-Heijboer H, et al., Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat 2008; 111: 303-11.
26. Passaperuma K, Warner E, Causer PA, et al., Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012; 107: 24-30.
27. Gareth ED, Nisha K, Yit L, et al., MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 2014; 145: 663-72.
28. Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al., Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy brca1 and brca2 mutation carriers: a prospective analysis. Ann Oncol Off J Eur Soc Med Oncol ESMO 2013; 24: 2029-35.
29. Obdeijn IM, Winter-Warnars GA, Mann RM, et al., Should we screen brca1 mutation carriers only with MRI? A multicenter study. Breast Cancer Res Treat 2014; 144: 577-82.
30. Kurian AW, Sigal BM, Plevritis SK,. Survival analysis of cancer risk reduction strategies for brca1/2 mutation carriers. J Clin Oncol Off J Am Soc Clin Oncol 2010; 28: 222-31.
31. Cheng L, Swartz MD, Zhao H, et al., Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-medicare. Cancer Epidemiol Biomarkers Prev 2012; 21: 800-9.
32. Litiere S, Werutsky G, Fentiman IS, et al., Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 2012; 13: 412-9.
33. Lord SJ, Marinovich ML, Patterson JA, et al., Incidence of metastatic breast cancer in an australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Med J Aust 2012; 196: 688-92.
34. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, et al., Brca1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res Off J Am Assoc Cancer Res 2007; 13: 7357-62.